BioSpace News Archive

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Guggenheim Healthcare Talks: Oncology Day.

Feb. 6, 2020 12:00 UTC Announces new strategic drug discovery partnership with Charles River Opens new office dedicated to drug discovery and potential development of novel CNS therapeutics BOSTON--( BUSINESS WIRE )-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain

The multiple presentations in one ASCO-SITC meeting session spotlight the growing interest in SEMA4D as a clinically relevant target implicated in multiple cancer types and highlights the potential of pepinemab antibody to neutralize SEMA4D in the treatment of cancer

CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2019 financial results and corporate update conference call and live audio webcast on Thursday, February 13th at 8:30 a.m. EST. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID num

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner, announced the Company will release its fourth quarter 2019 results before the market opens on Thursday, March 5, 2020, to be followed by a conference call at 8:30 a.m. (Eastern Time)

The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, one of the largest hyperbaric medical centers in the world, today announced that its Chief Medical Research Officer, Amir Hadanny, MD, will participate on a panel discussion at this year’s Synapse Summit, entitled, Aging Gracefully: Innovations Improving Life for Millions of Seniors.

Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold (TISvopra) – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit in patients from the ICONIC trial

Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. EST on Thursday, February 13, 2020 to report its fourth quarter and full year 2019 financial results and discuss business highlights.

Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Idea Forum | Oncology Day in New York City on Thursday, February 13, 2020 at 10 a.m. Eastern.

Digirad Corporation announced new financing to fund the growth strategy for its Building & Construction division for 2020.